Login to Your Account


Tivantinib misses OS endpoint in phase III liver cancer trial

By Michael Fitzhugh
Staff Writer

Friday, February 17, 2017

The oral c-Met inhibitor tivantinib missed its primary endpoint of improving overall survival vs. placebo in a phase III hepatocellular carcinoma (HCC) study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription


»

For Sales Inquiries,
http://clarivate.com/life-sciences/news/bioworld/#

 
Privacy Policy | Terms of Use | Copyright
 
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Clarivate Analytics